Study GIPF-001 is phase 3 study designed to determine the safety and efficacy of IFN-g 1b
administered by subcutaneous injection; compared to placebo in patients with IPF who are
unresponsive to steroids. 330 patients have been enrolled and were assigned to either a
IFN-g 1b group or a placebo group.
Male or Female, 20-79 years old